Skip to main content

Skyrizi vs Ilumya. What’s the difference?

Medically reviewed by Carmen Pope, BPharm. Last updated on July 26, 2024.

Official Answer by Drugs.com

Both Skyrizi and Ilumya are IL-23 monoclonal antibodies that may be given for the treatment of moderate to severe plaque psoriasis. There are several differences between them:

Comparative trials comparing Skyrizi to Ilumya are lacking; however, a trial that compared Skyrizi to Stelara showed that it has a fast onset of action with 44% of participants achieving PASI 90 by week four compared with only 19% of those administered Stelara.

There are several similarities between Skyrizi and Ilumya:

References

Read next

Who is the actress in the Skyrizi commercial?

The actress featuring in the Skyrizi commercials, “Day in the City” and “Downtown Getaway”, first aired on October 12, 2021, is Dana Deggs, born February 9th 1996 in Miami, Florida, USA. She has also appeared in several movies, notably Due Diligence (2008), Class Act (2010) and The Naked Brothers Band (2007). Continue reading

What are monoclonal antibodies?

Monoclonal antibodies (mAbs) are man-made proteins that mimic the natural antibodies produced by our immune systems. Monoclonal antibodies can be formulated into medicines to treat various types of illnesses, such as cancer, rheumatoid arthritis or psoriasis.

Continue reading

What's the dosing schedule for Skyrizi?

After your initial starter doses, you'll receive Skyrizi as subcutaneous (under the skin) maintenance dose every 12 weeks (4 times per year) to treat either plaque psoriasis or psoriatic arthritis, or every 8 weeks (6 times per year) to treat either Crohn's disease or ulcerative colitis. You can self-administer these injections at home after proper training from your healthcare provider. Continue reading

See also:

Related medical questions

Drug information

Related support groups